Secure your source for quality antibody production. Learn how our experience and flexibility can meet your needs for both small scale and large scale production.
Learn how our whole slide imaging and precision AI-driven quantitative image analysis can support your drug discovery and development projects.
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
September 14-17, 2025 Athens, Greece Booth #A38 EUROTOX is the Federation of European Toxicologists and European Societies of Toxicology, which together groups approximately 6,000 ...
November 9-13, 2025 Long Beach, CA Booth #1613 Each fall since 1950, the American Association for Laboratory Animal Science has held its annual National Meeting. During the five da...
November 15-19, 2025 San Diego, CA Booth #2135 Each year, scientists from around the world congregate to discover new ideas, share their research, and experience the best the field...
Dale Wright and Brian Bond from Inotiv discuss the importance of taking a holistic approach to glucagon-like peptide-1 re...
May 7, 2025 — Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue de...
April 23, 2025 WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2025 Inotiv. All Rights Reserved.